Lourdes Lago
Payments from drug & device makers
Across 90 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$672
- Eisai Inc.$337
- Merz Pharmaceuticals, LLC$241
- Teva Pharmaceuticals USA, Inc.$167
- Acadia Pharmaceuticals Inc$145
- Lundbeck LLC$82
- plus $759 from 19 others
What the payments were for
- Food & beverage$2,31596%
- Education$874%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $672 |
| Eisai Inc. | 12 | $337 |
| Merz Pharmaceuticals, LLC | 6 | $241 |
| Teva Pharmaceuticals USA, Inc. | 7 | $167 |
| Acadia Pharmaceuticals Inc | 2 | $145 |
| Lundbeck LLC | 3 | $82 |
| Banner Life Sciences, LLC | 3 | $82 |
| MDD US Operations, LLC | 1 | $82 |
| Cycle Pharmaceuticals Inc | 2 | $65 |
| Neurocrine Biosciences, Inc. | 3 | $56 |
| Lilly USA, LLC | 2 | $55 |
| Argenx US, Inc. | 2 | $49 |
| C2n Diagnostics, LLC | 2 | $47 |
| Adamas Pharmaceuticals, Inc. | 2 | $45 |
| Livanova USA, Inc. | 1 | $44 |
| Abbott | 2 | $41 |
| Tanabe Pharma America, Inc. | 1 | $33 |
| SK Life Science, Inc. | 1 | $33 |
| GE HealthCare | 2 | $25 |
| Amgen | 1 | $24 |
| EMD Serono, Inc. | 1 | $19 |
| Biogen | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Corium, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,403 in reported general payments places this provider in the 45th percentile of 1,434 neurology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 13 | $63,780 |
| Nurtec OdtRimegepant Sulfate | 14 | $21,903 |
| Memantine Hcl ErMemantine Hcl | 172 | $19,463 |
| Rivastigmine | 87 | $16,234 |
| Memantine Hcl | 673 | $8,806 |
| RytaryCarbidopa/Levodopa | 16 | $8,370 |
| FycompaPerampanel | 11 | $6,410 |
| Rasagiline Mesylate | 25 | $6,403 |
| Donepezil Hcl | 965 | $5,797 |
| Pregabalin | 102 | $5,728 |
| Gabapentin | 457 | $4,794 |
| Levetiracetam | 176 | $3,906 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 338 | $3,680 |
| Oxcarbazepine | 30 | $2,715 |
| Carbamazepine ErCarbamazepine | 33 | $2,493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $167 | $63,78013 claims |
| Eisai Inc.Fycompa | $337 | $6,41011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,434 neurology providers in Florida.
Other neurology in Miami
- Michael PfefferMiami$24.5M
- Silvia DelgadoMiami$11M
- Angel CarrascoMiami$10.3M
- Michael BenatarMiami$5.4M
- Kottil RammohanMiami$5M
- Macarena de la FuenteMiami$4.9M
- Victor FaradjiMiami$4M
- Brad HerskowitzMiami$3.1M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.